scholarly journals Minimal-risk traumatic brain injury management without neurosurgical consultation

2020 ◽  
Vol 13 (2) ◽  
pp. 80-85
Author(s):  
Elizabeth Starbuck Compton ◽  
Benjamin Allan Smallheer ◽  
Nicholas Russell Thomason ◽  
Michael S. Norris ◽  
Mina Faye Nordness ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Minimal Risk ◽  
Injury Management

Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury

2020 ◽  
pp. 107385842096107
Author(s):  
Zaynab Shakkour ◽  
Karl John Habashy ◽  
Moussa Berro ◽  
Samira Takkoush ◽  
Samar Abdelhady ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Drug Administration ◽  
Neurological Disorders ◽  
De Novo ◽  
Food And Drug Administration ◽  
Drug Repurposing ◽  
Adverse Outcomes ◽  
Minimal Risk ◽  
Wide Range

Traumatic brain injury (TBI) remains a significant leading cause of death and disability among adults and children globally. To date, there are no Food and Drug Administration–approved drugs that can substantially attenuate the sequelae of TBI. The innumerable challenges faced by the conventional de novo discovery of new pharmacological agents led to the emergence of alternative paradigm, which is drug repurposing. Repurposing of existing drugs with well-characterized mechanisms of action and human safety profiles is believed to be a promising strategy for novel drug use. Compared to the conventional discovery pathways, drug repurposing is less costly, relatively rapid, and poses minimal risk of the adverse outcomes to study on participants. In recent years, drug repurposing has covered a wide range of neurodegenerative diseases and neurological disorders including brain injury. This review highlights the advances in drug repurposing and presents some of the promising candidate drugs for potential TBI treatment along with their possible mechanisms of neuroprotection. Edaravone, glyburide, ceftriaxone, levetiracetam, and progesterone have been selected due to their potential role as putative TBI neurotherapeutic agents. These drugs are Food and Drug Administration–approved for purposes other than brain injuries; however, preclinical and clinical studies have shown their efficacy in ameliorating the various detrimental outcomes of TBI.

R3-Survey of traumatic brain injury management in European Brain IT centres year 2001

2004 ◽  
Vol 30 (6) ◽  
pp. 1058-1065 ◽  
Author(s):  
P. Enblad ◽  
P. Nilsson ◽  
I. Chambers ◽  
G. Citerio ◽  
H. Fiddes ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Injury Management ◽  
European Brain

scholarly journals Current pre-hospital traumatic brain injury management in China

2014 ◽  
Vol 5 (4) ◽  
pp. 245 ◽  
Author(s):  
Kou Kou ◽  
Xiang-yu Hou ◽  
Jian-dong Sun ◽  
Kevin Chu
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Injury Management

The Management of Traumatic Brain Injury

2018 ◽  
pp. 83-96
Author(s):  
Jeremy G. Stone ◽  
David M. Panczykowski ◽  
David O. Okonkwo
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Clinical Assessment ◽  
Cerebral Perfusion ◽  
Injury Severity ◽  
Secondary Brain Injury ◽  
Second Line ◽  
Injury Management ◽  
Imaging Characteristics ◽  
System P

The management of traumatic brain injury necessitates a multidisciplinary approach with medical and surgical therapies employed based on rapid clinical assessment of injury severity and imaging characteristics. Therapy aims to prevent secondary brain injury through multifactorial interventions primarily focusing on prevention of cerebral hypoxemia and aggressive control of intracranial pressure (ICP). This chapter covers epidemiology, pathophysiology, clinical assessment, and both medical and surgical management of traumatic brain injury. Management topics include appropriate monitoring, first- and second-line therapy for ICP and cerebral perfusion pressure, hypoxia, seizure prophylaxis, hyperpyrexia, glycemic control, fluids and electrolytes, nutrition, and prophylaxis for venous thromboembolism and the gastrointestinal system.

Sign in / Sign up

Export Citation Format

Share Document